Page 31 - துறை ஆஃப் நரம்பியல் அறுவை சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First patient treated in CereVasc clinical trial of eShunt™ System for communicating hydrocephalus Investigational device has the potential to transform a half-century-old standard of care News provided by Share this article Share this article BOSTON, Feb. 10, 2021 /PRNewswire/ CereVasc, Inc., a clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, has treated the first patient in a study of its eShunt System, an investigational device intended to treat communicating hydrocephalus (CH), one of the most common neurological conditions worldwide. Representing the first minimally invasive treatment for CH, the eShunt device offers the potential to result in significant benefits over current treatment, a half-century-old neurosurgical procedure associated with frequent failure, infection risk and high costs. Study data will be available in 2021.

United statesBuenos airesDistrito federalEl salvadorTufts medical centerDan levangieClinica sagrada familiaCarl heilmanPedro lylykAdel malekDiana grayUniversity of buenos airesUniversity of ciencias empresarialesDepartment of vascular medicineDepartment of neurosurgeryHydrocephalus association